This clinical trial is focused on studying a condition known as ischemic stroke, which occurs when a blood clot blocks a blood vessel in the brain, leading to reduced blood flow and potential brain damage. The study is investigating a treatment called intra-arterial thrombolysis, which involves delivering medication directly into the arteries to dissolve clots. The medication used in this study is called Actilyse, which contains the active substance alteplase. This treatment is being compared to not using the additional intra-arterial thrombolysis after a successful initial treatment to see if it improves recovery outcomes.

The purpose of the study is to determine if adding intra-arterial thrombolysis can lead to better recovery in patients who have already had a successful initial treatment for their stroke. Participants in the study will receive either the additional treatment with Actilyse or no additional treatment after their initial stroke treatment. The study will monitor participants over a period of 90 days to assess their recovery and any changes in their ability to perform daily activities. The study aims to see if the additional treatment can help improve the overall recovery and reduce disability caused by the stroke.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include evaluations of their neurological function and overall health. The study will also monitor for any potential side effects or complications related to the treatment. The results of this study could provide valuable information on the effectiveness of intra-arterial thrombolysis in improving outcomes for patients who have experienced an ischemic stroke.